Market Research Logo

Colitis - Pipeline Review, H2 2016

Colitis - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Colitis - Pipeline Review, H2 2016’, provides an overview of the Colitis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Colitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Colitis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Colitis
  • The report reviews pipeline therapeutics for Colitis by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Colitis therapeutics and enlists all their major and minor projects
  • The report assesses Colitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Colitis
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Colitis
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Colitis pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Colitis Overview
Therapeutics Development
Pipeline Products for Colitis - Overview
Pipeline Products for Colitis - Comparative Analysis
Colitis - Therapeutics under Development by Companies
Colitis - Therapeutics under Investigation by Universities/Institutes
Colitis - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Colitis - Products under Development by Companies
Colitis - Products under Investigation by Universities/Institutes
Colitis - Companies Involved in Therapeutics Development
Aerpio Therapeutics, Inc.
Akebia Therapeutics, Inc.
Amorepacific Corporation
Bayer AG
Bristol-Myers Squibb Company
Cosmo Pharmaceuticals S.p.A
Dr. Falk Pharma GmbH
EA Pharma Co Ltd
Euroscreen S.A.
Genfit SA
Immuron Limited
Innate Pharma S.A.
Peptinov SAS
Pfizer Inc.
Prokarium Limited
RDD Pharma Ltd.
Saniona AB
Synovo GmbH
Colitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AcTMP-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-4924 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AKB-6899 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AN-346 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense RNAi Oligonucleotides to Inhibit TNFalpha for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APY-0201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BC-1215 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMS-986104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
budesonide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Clostridium difficile vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CSY-0073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs to Antagonize TRP Channel for Inflammatory Diseases and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elafibranor - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ESN-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-124E - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-33 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
mesalamine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NK-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PAC-14028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit NFkB for Colitis and Enteritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06425090 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PPV-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDD-2007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit TNF-Alpha for Crohn's Disease and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rifamycin CR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RP-182 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Sphingosine Kinase for Colorectal Cancer and Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Inhibit Panx1 for Colitis and Inflammatory Bowel Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL12 and IL23 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target IL23 for Colitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZK-216348 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Colitis - Dormant Projects
Colitis - Discontinued Products
Colitis - Product Development Milestones
Featured News & Press Releases
Jun 06, 2016: Cosmo Announces Successful Outcome Of Phase III Clinical Trial For Rifamycin SV MMX
Jul 11, 2013: Mylan Confirms First-to-File Patent Challenge Relating to CANASA
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Colitis, H2 2016
Number of Products under Development for Colitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Investigation by Universities/Institutes, H2 2016
Colitis - Pipeline by Aerpio Therapeutics, Inc., H2 2016
Colitis - Pipeline by Akebia Therapeutics, Inc., H2 2016
Colitis - Pipeline by Amorepacific Corporation, H2 2016
Colitis - Pipeline by Bayer AG, H2 2016
Colitis - Pipeline by Bristol-Myers Squibb Company, H2 2016
Colitis - Pipeline by Cosmo Pharmaceuticals S.p.A, H2 2016
Colitis - Pipeline by Dr. Falk Pharma GmbH, H2 2016
Colitis - Pipeline by EA Pharma Co Ltd, H2 2016
Colitis - Pipeline by Euroscreen S.A., H2 2016
Colitis - Pipeline by Genfit SA, H2 2016
Colitis - Pipeline by Immuron Limited, H2 2016
Colitis - Pipeline by Innate Pharma S.A., H2 2016
Colitis - Pipeline by Peptinov SAS, H2 2016
Colitis - Pipeline by Pfizer Inc., H2 2016
Colitis - Pipeline by Prokarium Limited, H2 2016
Colitis - Pipeline by RDD Pharma Ltd., H2 2016
Colitis - Pipeline by Saniona AB, H2 2016
Colitis - Pipeline by Synovo GmbH, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Colitis - Dormant Projects, H2 2016
Colitis - Dormant Projects (Contd..1), H2 2016
Colitis - Dormant Projects (Contd..2), H2 2016
Colitis - Discontinued Products, H2 2016
List of Figures
Number of Products under Development for Colitis, H2 2016
Number of Products under Development for Colitis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report